Home>Tag: extracorporeal
Dec 17 2020

Halberd Corporation Pursues Extracorporeal Radio Frequency Treatment Against Covid-19

By |2020-12-16T20:11:40-05:00December 17th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, December 17, 2020 – Halberd Corp. (OTC PINK: "HALB") announced they are pursuing development of their latest extracorporeal treatment variation in the fight against COVID-19.  Halberd’s provisional patent application, “Method For Treating And Curing Covid-19 Infection By Utilizing Radio Frequency Extracorporeally To Eradicate The Virus,” was filed last month.  The procedure is ...

Dec 10 2020

Halberd Corporation Discusses Positive Antibody Test Results Against COVID-19 with The Stock Day Podcast

By |2020-12-09T21:39:40-05:00December 10th, 2020|Featured, Investor News, News|1 Comment

Phoenix, December 10th, 2020 (Newsfile Corp.) -- The Stock Day Podcast welcomed Halberd Corporation (HALB) (“the Company”), a company with a patented extracorporeal treatment applicable to many hard-to-cure blood-borne and neurological diseases, including Covid-19, other viruses, and PTSD. President and CEO of the Company, William A. Hartman, joined Stock Day host Everett Jolly. Jolly began ...

Nov 19 2020

Halberd Corporation Files for Patent Protection on Covid-19 Extracorporeal Treatment Variation

By |2020-11-18T19:10:48-05:00November 19th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, November 19, 2020 – Halberd Corp. (OTC PINK: "HALB") reported the filing of a provisional patent application on a variation of Halberd’s patented extracorporeal method to treat/eradicate Covid-19 from a patient’s blood.  By using an extracorporeal (outside the body) treatment method, the patient is exposed to far fewer potential negative side effects ...

Oct 27 2020

Halberd Corp. Retains Prestigious Patent Law Firm on Covid-19-Related and Other Disease Technologies

By |2020-10-26T18:49:33-04:00October 27th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, October 27, 2020 – Halberd Corporation (OTC PINK: "HALB") has retained the services of a prestigious Pittsburgh, PA law firm, Ference & Associates, to handle its intellectual property matters.  The initial application focuses on patenting Halberd’s base Covid-19 antibody as well as an entire new class of antibody conjugate. The primary attorney ...

Sep 28 2020

Arizona State University/Halberd Pursue Nasal Spray As Covid-19 Preventative/Treatment Based On Children’s Natural Immunity

By |2020-09-27T19:42:54-04:00September 28th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, September 28, 2020 – Children are far less susceptible than adults to the Coronavirus (1, 2).  Halberd Corporation’s (OTC PINK: "HALB") scientists have determined the reason may be that adults have far more Angiotensin-Converting Enzyme 2 (ACE2) receptors in nasal membrane epithelial cells.  ACE2 (3) is a membrane protein expressed in many ...

Jul 27 2020

Retired NFL Great Carl Eller Joins Halberd Corporation

By |2020-07-30T17:30:57-04:00July 27th, 2020|Featured, Investor News, News|0 Comments

Will Assist with Covid-19 Efforts and the Brain Jackson Center, PA, July 27, 2020 – Halberd Corp. (OTC PINK: "HALB") announced the appointment of Carl Eller, retired NFL Pro Football Hall of Famer, and President of the NFL Retired Players Association as a consultant.  Mr. Eller’s expertise and contacts will be leveraged as part of ...

Jul 16 2020

Halberd Advances the Treatment of COVID-19 Utilizing Laser Technology

By |2020-07-21T11:29:21-04:00July 16th, 2020|Featured, Investor News|0 Comments

Jackson Center, PA, July 16, 2020 – Halberd Corp. (OTC PINK: "HALB") intends to use laser technology to eradicate the COVID-19 Coronavirus. This patent pending treatment introduces one or more fluorescent antibody-antigen complexing agents to bind with the target antigen(s) (i.e., Covid-19 target antigens). This will allow the virus to be seen and located, and ...

Jul 7 2020

COVID-19 Cytokine Storm, Coronavirus’ Deadliest Stage – Halberd’s US Patent Pending Treatment Now Explained!

By |2020-07-06T19:47:51-04:00July 7th, 2020|Featured, News, Technology|0 Comments

Jackson Center, PA, July 7, 2020 – Halberd Corp. (OTC PINK: "HALB") today explains the second of three (3) COVID -19 (Coronavirus) patent pending treatments - “Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients” - which was filed with the U.S. Patent and Trademark Office on ...

Jun 15 2020

Halberd Designated “Pink Current Information” by OTC and Continues Technology Progress

By |2020-06-21T04:55:39-04:00June 15th, 2020|Featured, News, Technology|0 Comments

Jackson Center, PA, June 15, 2020 –Halberd Corporation (OTC Pink: HALB) announced that OTC Markets has completed its background investigation and analysis of all filings by Halberd Corporation and now designates Halberd Corporation as "Pink Current Information". William A. Hartman, newly appointed Chairman, President and CEO explains, “Now that Halberd has been designated by OTC ...

Go to Top